Anticancer Drug — Friend or Foe

Kant: Friend or Foe of the Believer? Plantinga and Other American Christian Responses to Kant's Epistemology

Apocrine Metaplasia in Intraductal Papilloma with Foci of DCIS: A Friend or Foe?

Malignant papillary neoplasms of the breast comprise a number of microscopically distinct lesions, where apocrine metaplasia is commonly found in papillomas compared to other papillary lesions including papillary carcinomas. However, association of apocrine metaplasia in papilloma with Ductal Carcinoma in Situ (DCIS) is not very well defined. The lesions with apocrine metaplasia are not only di...

Cellular senescence in cancer treatment: friend or foe?

Damage to DNA, the prime target of anticancer therapy, triggers programmed cellular responses. In addition to apoptosis, therapy-mediated premature senescence has been identified as another drug-responsive program that impacts the outcome of cancer therapy. Here, we discuss whether induction of senescence is a beneficial or, rather, a detrimental consequence of the therapeutic intervention.

NOACs; Friend or Foe?

New oral anticoagulants (NOAC’s) are becoming more popular as antithrombotic agents for the prevention of venous thromboembolism in atrial fibrillation and as prophylaxis in hip and knee surgery. With simple administration, rapid onset, few drug interactions and the absence of coagulation monitoring, NOAC’s appear as a friend in the prevention of thromboembolic events. Undoubtedly patients woul...

NLRX1: friend or foe?